Abstract:Simultaneous inhibition of both tumor growth and metastasis is the key to treating metastatic cancer, yet the development of effective drug delivery systems represents a great challenge since multimodal therapeutic agents must be rationally combined to overcome the biological mechanisms underpinning tumor cell proliferation and invasion. In this context, we report a hybrid therapeutic nanoscale platform that incorporates an anti-proliferative drug, doxorubicin (DOX), and an anti-NF-κB agent, p65-shRNA, for effective treatment of metastatic breast cancer. In our design, we first conjugated DOX via an acid-labile linker onto gold nanorods that were pre-modified with the tumor targeting peptide RGD and a positively charged, disulfide cross-linked short polyethylenimines (DSPEI), and then incorporated shRNA through electrostatic complexation with DSPEI. We show that this "all in one" nanotherapeutic system (RDG/shRNA@DOX) can be effectively internalized through RGD-mediated endocytosis, followed by stimuli-responsive intracellular co-release of DOX and shRNA. Our in vitro experiments suggest that this multimodal system can significantly inhibit cell proliferation, angiogenesis, and invasion of metastatic MDA-MB-435 cancer cells. Systemic administration of RDG/shRNA@DOX into a metastatic mouse model led to enhanced tumor accumulation, and, most importantly, significant inhibition of in situ tumor growth and almost complete suppression of tumor metastasis. We believe this hybrid multimodal nanotherapeutic system provides important insight into the rational design of therapeutic systems for the effective treatment of metastatic carcinoma.STATEMENT OF SIGNIFICANCE:The key to successfully treat metastatic cancer is the simultaneous inhibition of both tumor growth and metastasis. This represents a great challenge for the design of drug delivery systems since multimodal therapeutic agents must be rationally combined to overcome the respective biological mechanisms underpinning tumor cell proliferation and invasion. Toward this end, we developed a hybrid nanomedicine platform that incorporates an anti-proliferative drug, doxorubicin (DOX), and an anti-NF-κB agent, p65-shRNA, for effective treatment of metastatic breast cancer. We showed that this multimodal system (RDG/shRNA@DOX) enhanced tumor accumulation, led to prolonged circulation, and most importantly, significant inhibition of in situ tumor growth and almost complete suppression of tumor metastasis. We believe this hybrid multimodal nanotherapeutic system provides significant insight into the rational design of therapeutic systems for the effective treatment of metastatic cancer.

Protein Stabilized Polymeric Nanoparticles Inspired Relay Drug Delivery for Tackling Post-Chemotherapeutic Metastasis

Supramolecular polymeric prodrug micelles for efficient anticancer drug delivery

Polymer-lipid Hybrid Nanoparticles Synchronize Pharmacokinetics of Co-Encapsulated Doxorubicin-Mitomycin C and Enable Their Spatiotemporal Co-Delivery and Local Bioavailability in Breast Tumor.

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Stimuli-sensitive Biomimetic Nanoparticles for the Inhibition of Breast Cancer Recurrence and Pulmonary Metastasis

Co-delivery nanoparticle to overcome metastasis promoted by insufficient chemotherapy

Coadministration of Chemotherapy and PI3K/Akt Pathway Treatment with Multistage Acidity/cathb Enzyme-Responsive Nanocarriers for Inhibiting the Metastasis of Breast Cancer.

Tumor-Cell-Surface Adherable Peptide-Drug Conjugate Prodrug Nanoparticles Inhibit Tumor Metastasis and Augment Treatment Efficacy.

Creatine Based Polymer for Codelivery of Bioengineered MicroRNA and Chemodrugs Against Breast Cancer Lung Metastasis.

Rational Design of Multimodal Therapeutic Nanosystems for Effective Inhibition of Tumor Growth and Metastasis.

Combating multidrug resistance and metastasis of breast cancer by endoplasmic reticulum stress and cell-nucleus penetration enhanced immunochemotherapy

Stromal Barrier-Dismantled Nanodrill-Like and Cancer Cell-Targeted Ph-Responsive Polymeric Micelles for Further Enhancing the Anticancer Efficacy of Doxorubicin

Therapeutic Nanocarriers Inhibit Chemotherapy‐Induced Breast Cancer Metastasis

Enhanced chemotherapy and anti-metastasis with in situ nanosphere-to-nanofiber transition

Primary Tumor and Pre-Metastatic Niches Co-Targeting "Peptides-Lego" Hybrid Hydroxyapatite Nanoparticles for Metastatic Breast Cancer Treatment

Self-assembled Ternary Hybrid Nanodrugs for Overcoming Tumor Resistance and Metastasis

ROS-Switchable Polymeric Nanoplatform with Stimuli-Responsive Release for Active Targeted Drug Delivery to Breast Cancer.

Supramolecular nanoparticles based on elastin-like peptides modified capsid protein as drug delivery platform with enhanced cancer chemotherapy efficacy

Enzymatically Transformable Polymersome‐Based Nanotherapeutics to Eliminate Minimal Relapsable Cancer

Enhancing Cancer Targeting and Anticancer Activity by A Stimulus-Sensitive Multifunctional Polymer-Drug Conjugate

A targeted nanoplatform co-delivery of pooled siRNA and doxorubicin for reversing of multidrug resistance in breast cancer